Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 108

1.

Interventional MRI-guided putaminal delivery of AAV2-GDNF for a planned clinical trial in Parkinson's disease.

Richardson RM, Kells AP, Rosenbluth KH, Salegio EA, Fiandaca MS, Larson PS, Starr PA, Martin AJ, Lonser RR, Federoff HJ, Forsayeth JR, Bankiewicz KS.

Mol Ther. 2011 Jun;19(6):1048-57. doi: 10.1038/mt.2011.11. Epub 2011 Feb 22.

2.

Clinically relevant effects of convection-enhanced delivery of AAV2-GDNF on the dopaminergic nigrostriatal pathway in aged rhesus monkeys.

Johnston LC, Eberling J, Pivirotto P, Hadaczek P, Federoff HJ, Forsayeth J, Bankiewicz KS.

Hum Gene Ther. 2009 May;20(5):497-510. doi: 10.1089/hum.2008.137.

3.

Glial-derived neurotrophic factor gene transfer for Parkinson's disease: anterograde distribution of AAV2 vectors in the primate brain.

Kells AP, Forsayeth J, Bankiewicz KS.

Neurobiol Dis. 2012 Nov;48(2):228-35. doi: 10.1016/j.nbd.2011.10.004. Epub 2011 Oct 14. Review.

4.

Anterograde axonal transport of AAV2-GDNF in rat basal ganglia.

Ciesielska A, Mittermeyer G, Hadaczek P, Kells AP, Forsayeth J, Bankiewicz KS.

Mol Ther. 2011 May;19(5):922-7. doi: 10.1038/mt.2010.248. Epub 2010 Nov 23.

5.

Safety evaluation of AAV2-GDNF gene transfer into the dopaminergic nigrostriatal pathway in aged and parkinsonian rhesus monkeys.

Su X, Kells AP, Huang EJ, Lee HS, Hadaczek P, Beyer J, Bringas J, Pivirotto P, Penticuff J, Eberling J, Federoff HJ, Forsayeth J, Bankiewicz KS.

Hum Gene Ther. 2009 Dec;20(12):1627-40. doi: 10.1089/hum.2009.103.

6.

Image-guided convection-enhanced delivery of GDNF protein into monkey putamen.

Gimenez F, Krauze MT, Valles F, Hadaczek P, Bringas J, Sharma N, Forsayeth J, Bankiewicz KS.

Neuroimage. 2011 Jan;54 Suppl 1:S189-95. doi: 10.1016/j.neuroimage.2010.01.023. Epub 2010 Jan 18.

PMID:
20080195
7.

Real-time MR imaging with Gadoteridol predicts distribution of transgenes after convection-enhanced delivery of AAV2 vectors.

Su X, Kells AP, Salegio EA, Richardson RM, Hadaczek P, Beyer J, Bringas J, Pivirotto P, Forsayeth J, Bankiewicz KS.

Mol Ther. 2010 Aug;18(8):1490-5. doi: 10.1038/mt.2010.114. Epub 2010 Jun 15. Erratum in: Mol Ther. 2012 Feb;20(2):468. Salegio, Ernesto Aguilar [corrected to Salegio, Ernesto A].

8.

Convection-enhanced delivery of adeno-associated virus type 2 (AAV2) into the striatum and transport of AAV2 within monkey brain.

Hadaczek P, Kohutnicka M, Krauze MT, Bringas J, Pivirotto P, Cunningham J, Bankiewicz K.

Hum Gene Ther. 2006 Mar;17(3):291-302.

PMID:
16544978
9.

Properly scaled and targeted AAV2-NRTN (neurturin) to the substantia nigra is safe, effective and causes no weight loss: support for nigral targeting in Parkinson's disease.

Bartus RT, Brown L, Wilson A, Kruegel B, Siffert J, Johnson EM Jr, Kordower JH, Herzog CD.

Neurobiol Dis. 2011 Oct;44(1):38-52. doi: 10.1016/j.nbd.2011.05.026. Epub 2011 Jun 17.

PMID:
21704161
10.

Real-time MR Imaging With Gadoteridol Predicts Distribution of Transgenes After Convection-enhanced Delivery of AAV2 Vectors.

Su X, Kells AP, Salegio EA, Richardson RM, Hadaczek P, Beyer J, Bringas J, Pivirotto P, Forsayeth J, Bankiewicz KS.

Mol Ther. 2010 Aug;18(8):1490-1495. doi: 10.1038/mt.2010.114. Epub 2016 Dec 6.

11.

Accuracy of direct magnetic resonance imaging-guided placement of drug infusion cannulae.

Chittiboina P, Heiss JD, Lonser RR.

J Neurosurg. 2015 May;122(5):1173-9. doi: 10.3171/2014.11.JNS131888. Epub 2015 Jan 16.

12.

Functional effects of AAV2-GDNF on the dopaminergic nigrostriatal pathway in parkinsonian rhesus monkeys.

Eberling JL, Kells AP, Pivirotto P, Beyer J, Bringas J, Federoff HJ, Forsayeth J, Bankiewicz KS.

Hum Gene Ther. 2009 May;20(5):511-8. doi: 10.1089/hum.2008.201.

13.

Regeneration of the MPTP-lesioned dopaminergic system after convection-enhanced delivery of AAV2-GDNF.

Kells AP, Eberling J, Su X, Pivirotto P, Bringas J, Hadaczek P, Narrow WC, Bowers WJ, Federoff HJ, Forsayeth J, Bankiewicz KS.

J Neurosci. 2010 Jul 14;30(28):9567-77. doi: 10.1523/JNEUROSCI.0942-10.2010.

14.

AAV2-mediated gene delivery to monkey putamen: evaluation of an infusion device and delivery parameters.

Sanftner LM, Sommer JM, Suzuki BM, Smith PH, Vijay S, Vargas JA, Forsayeth JR, Cunningham J, Bankiewicz KS, Kao H, Bernal J, Pierce GF, Johnson KW.

Exp Neurol. 2005 Aug;194(2):476-83.

15.

Titer and product affect the distribution of gene expression after intraputaminal convection-enhanced delivery.

Emborg ME, Hurley SA, Joers V, Tromp do PM, Swanson CR, Ohshima-Hosoyama S, Bondarenko V, Cummisford K, Sonnemans M, Hermening S, Blits B, Alexander AL.

Stereotact Funct Neurosurg. 2014;92(3):182-94. doi: 10.1159/000360584. Epub 2014 Jun 12.

16.

Optimal region of the putamen for image-guided convection-enhanced delivery of therapeutics in human and non-human primates.

Yin D, Valles FE, Fiandaca MS, Bringas J, Gimenez F, Berger MS, Forsayeth J, Bankiewicz KS.

Neuroimage. 2011 Jan;54 Suppl 1:S196-203. doi: 10.1016/j.neuroimage.2009.08.069. Epub 2009 Sep 15.

17.

Intraputamenal infusion of GDNF in aged rhesus monkeys: distribution and dopaminergic effects.

Ai Y, Markesbery W, Zhang Z, Grondin R, Elseberry D, Gerhardt GA, Gash DM.

J Comp Neurol. 2003 Jun 23;461(2):250-61.

PMID:
12724841
18.

Increased brain bio-distribution and chemical stability and decreased immunogenicity of an engineered variant of GDNF.

Smith RC, O'Bryan LM, Mitchell PJ, Leung D, Ghanem M, Wilson JM, Hanson JC, Sossick S, Cooper J, Huang L, Merchant KM, Lu J, O'Neill MJ.

Exp Neurol. 2015 May;267:165-76. doi: 10.1016/j.expneurol.2015.03.002. Epub 2015 Mar 12.

19.

Safety and tolerability of magnetic resonance imaging-guided convection-enhanced delivery of AAV2-hAADC with a novel delivery platform in nonhuman primate striatum.

San Sebastian W, Richardson RM, Kells AP, Lamarre C, Bringas J, Pivirotto P, Salegio EA, Dearmond SJ, Forsayeth J, Bankiewicz KS.

Hum Gene Ther. 2012 Feb;23(2):210-7. doi: 10.1089/hum.2011.162. Epub 2012 Jan 26.

20.

Efficient gene therapy for Parkinson's disease using astrocytes as hosts for localized neurotrophic factor delivery.

Drinkut A, Tereshchenko Y, Schulz JB, Bähr M, Kügler S.

Mol Ther. 2012 Mar;20(3):534-43. doi: 10.1038/mt.2011.249. Epub 2011 Nov 15.

Supplemental Content

Support Center